Compare Eli Lilly And Co (LLY) vs LyondellBasell Industries NV (LYB) Price & Performance

Eli Lilly (LLY) trades at $1,179.27, down 0.79% on the day, with a bullish technical outlook and strong fundamental momentum. The stock has consistently beaten earnings estimates, with Q2 2026 EPS of $8.38 surpassing the $6.40 expectation. Revenue surged to $65.18 billion in 2025, driving a net income margin of 33.53%. Recent news highlights promising pipeline developments in weight-loss and diabetes drugs, reinforcing its market leadership.

The outlook remains positive given robust revenue growth, high profitability, and analyst consensus favoring buys. Key risks include competitive pressures in the obesity drug market and execution challenges in scaling production. With a consensus price target of $1,350, representing ~14% upside, the stock offers growth potential but requires monitoring of pipeline progress and market dynamics.

LYB trades at $60.03, up 2.63% today, with a bearish technical signal despite recent earnings beats. The company reported strong Q2 2026 results with EPS of $4.30 beating expectations of $3.44, but faces fundamental challenges with negative net income margin of -1.13% and declining revenue from $50.5B in 2022 to $30.2B in 2025. Analyst consensus remains divided with 45% buy and 45% hold ratings, targeting $69.38 average price.

LYB shows operational resilience with improving cash flow projections for 2026, but faces significant headwinds from declining profitability and competitive pressures. The dividend yield remains attractive but sustainability concerns persist given the negative earnings trend. Near-term upside exists if operational improvements continue, though investors should monitor debt levels and chemical sector cyclicality.